The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Revumenib plus IC in newly diagnosed NPM1-mutated AML: REVEAL-ND NPM1 trial-in-progress
In this video, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, introduces the REVEAL-ND NPM1 trial (NCT07211958), a Phase III study designed to assess the safety and efficacy of revumenib in combination with intensive chemotherapy (IC) in patients with newly diagnosed NPM1-mutated acute myeloid leukemia (AML). Dr Stein highlights the potential benefits of combining a menin inhibitor with intensive chemotherapy to improve outcomes for this patient population. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Revumenib, as everyone knows, has been approved for relapse and refractory acute leukemia with a KMT2A rearrangement and relapsed/refractory AML with an NPM1 mutation. We’re now taking Revumenib, moving it into the newly diagnosed setting in combination with intensive chemotherapy and doing a randomized study to see if giving intensive chemotherapy with Revumenib is better or not as good as giving intensive chemotherapy alone for NPM1 mutant patients...
Revumenib, as everyone knows, has been approved for relapse and refractory acute leukemia with a KMT2A rearrangement and relapsed/refractory AML with an NPM1 mutation. We’re now taking Revumenib, moving it into the newly diagnosed setting in combination with intensive chemotherapy and doing a randomized study to see if giving intensive chemotherapy with Revumenib is better or not as good as giving intensive chemotherapy alone for NPM1 mutant patients. We’re excited about this trial. This trial is hopefully going to show us that adding a menin inhibitor to intensive chemotherapy is going to be better than not giving a menin inhibitor with intensive chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
